期刊文献+

普卢利沙星治疗急性尿路感染的临床多中心研究

原文传递
导出
摘要 目的评价普卢利沙星治疗急性尿路感染的临床疗效及安全性。方法将2013年1月—2014年1月在山东大学齐鲁医院就诊的尿路感染患者136例,随机分为观察组67例和对照组69例。观察组给予普卢利沙星片和盐酸左氧氟沙星片模拟片,2次/d,2片/次;对照组给予盐酸左氧氟沙星片和普卢利沙星片模拟片,2片/次,2次/d。两组均治疗7~10d。计量资料采用t检验,计数资料采用Х^2检验,P〈0.05为差异有统计学意义。结果观察组和对照组痊愈率分别为58.21%和68.15%,有效率分别为97.01%和97.10%,细菌清除率分别为94.34%和94.92%,差异均无统计学意义(P〉0.05)。纸片法药敏试验显示,致病菌对试验药和对照药的敏感率分别为98.21%和96.43%,差异无统计学意义(P〉0.05)。两组不良反应发生率分别为7.46%和5。80%,差异无统计学意义(P〉0.05)。结论普卢利沙星治疗急性尿路感染安全有效,值得临床应用。
作者 李福琴 胡昭
出处 《社区医学杂志》 2014年第10期32-34,共3页 Journal Of Community Medicine
基金 国家食品药品监督管理局临床研究项目(2004L04943)
  • 相关文献

参考文献9

  • 1Yagi Y, Shibutani S, Hodoshima N, et al. Involvement of multiple transport systems in the disposition of an active metabolite of a pro- drug - type new quinolone antibiotic, Prulifloxacin [ J ]. Drug Metab Pharmacokinet,2003,18(6) :381 -389.
  • 2方利明,金艳,魏敏吉.氟喹诺酮类抗菌剂——普卢利沙星[J].中国医药导刊,2004,6(3):225-227. 被引量:20
  • 3Yoshida T, Mitsuhashi S. Antibacterial activity of NM394, the active form of prodmg NM441, A new Quinolone. Antimicrob Agents[ J ]. J Chemother, 1993,37 (4) :795 - 800.
  • 4Picollo R, Bfion N, Gualane V, et al. Phamacokinetics and tolerability of Prulifloxacin after single oral administration [ J ]. Drug Res, 2003,53 ( 3 ) :201 - 205.
  • 5江丽,杭太俊,沈建平,张银娣.血浆普卢利沙星活性代谢物的测定及其人体药动学研究[J].中国新药杂志,2006,15(4):307-310. 被引量:10
  • 6王金生,宋慈媛.新氟喹诺酮抗菌药NM441[J].国外医药(抗生素分册),1996,17(3):224-226. 被引量:11
  • 7陈小勇,彭润涛,江宇,李述平,陈颖,张润峰.广谱、高效、低毒的新喹诺酮类抗菌药——普卢利沙星[J].中国医药情报,2004,10(6):32-35. 被引量:6
  • 8Picollo R, Brion N, Gualano V, et al. Pharmacokinetics and tolerability of prulifloxacin after single oral administration [J]. Arzneimitte- forsch ,2003,53 (3) : 201 - 205.
  • 9Cannignani G, De Rose AF, Olivieri L, et al. Prulifloxacin versus cipmfloxacin in the treatment of adults with complicated urinary tract infections[ J ]. J Chemother,2005,17 (2) : 138 - 142.

二级参考文献21

  • 1方利明,金艳,魏敏吉.氟喹诺酮类抗菌剂——普卢利沙星[J].中国医药导刊,2004,6(3):225-227. 被引量:20
  • 2王金生,宋慈媛.新氟喹诺酮抗菌药NM441[J].国外医药(抗生素分册),1996,17(3):224-226. 被引量:11
  • 3Carlo Grassi, Enrica Salvatori, Maria Teresa Rosignoli, et al. Randomized, double - blind study of prulifioxacin versus ciprofloxacin in patients with Acut Exacerbations of Chronic Bronchitis. Respiration,2002; 69: 217~222
  • 4Maria Pia Montanari, Marina Mingoia, Pietro Emanuele Varaldo. In vitro antibacterial activities of AF3013, the actice metabolite of prulifloxacin, against nosocomial and community Italian isolates. Antimicrob Agents Chemother, 2001; 45(12): 3616~ 3622
  • 5Yoshio Okuyama, Kazuo Momota, Akira Morino. Pharmacokinetics of prudifloxacin 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single admiustration. Arzneim. Forsch./Drug Res, 1997; 47(Ⅰ): 276~ 284
  • 6Kura K, Fukui H, Fukui T, et al. General pharmacological studies of NM441 (1). Effect on center and peripheral nervous systems, gastrointestinal tract and smooth muscle. Jpn J Chemother, 1996; 44(Suppl.1): 113~ 128
  • 7Masakuni Ozaki, Masato Matsuda, Yoshifumi Tomii, et al. In vivo evaluation of NM441, a new thiazeto - quinoline derivative. Antimicrob Agents Chemother, 1991; 35(12): 2496- 2499
  • 8Katsuhiko Tougou, Akio Nakamura, Shuji Watanabe, et al. Paraoxonase has a major role in the hydrolysis of prulifloxacin(NM441), a prodrug of a new antibacterial agent. Drug Metab Dispos, 1998; 26:355- 359
  • 9vRossella Picollo, Nils Brion, Virginie Gualano, et al. Pharmacokinetics and tolerability of prulifloxacin after single oral administration.Arzneim. - Forsch./Drug Res, 2003; 53(3): 201 - 205
  • 10Masakuni Ozaki, Masato Matsuda, Yoshifumi Tomii, et al. In vitro antibacterial activity of a new quinolne, NM394. Antimicrob Agents Chemother, 1991;35(12): 2490- 2495

共引文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部